Pharma company Fresenius Kabi has announced the launch of Ganirelix Acetate Injection, a generic fertility drug. The medication is now available for immediate purchase from Fresenius Kabi in the form of 250 mcg/0.5 mL prefilled syringes.
Ganirelix Acetate Injection is primarily used to inhibit premature surges in luteinizing hormone (LH), a chemical that triggers reproductive processes like ovulation. It is specifically designed to aid women undergoing controlled ovarian hyperstimulation, a fertility therapy method. It is a generic medication that serves as a therapeutic equivalent to Organon’s Ganirelix Acetate injection, 250 mcg/0.5 mL.
Fresenius Kabi USA’s President and CEO, John Ducker commented: “We’re pleased to expand our Women’s Health portfolio with the introduction of Ganirelix Acetate Injection, which was developed to provide hopeful parents with more choice when navigating in vitro fertilization and other fertility treatments.”
The Ganirelix Acetate Injection joins Fresenius Kabi’s existing Women’s Health portfolio, which includes Chorionic Gonadotropin for Injection, USP (hCG) and Progesterone Injection, USP. The company has plans to further expand its women’s health offerings, aiming to meet the increasing demand for reproductive health options in the United States.
